Skip to main content

AL Amyloidosis clinical trials at UC Irvine

2 in progress, 0 open to eligible people

Showing trials for
  • S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

    Sorry, in progress, not accepting new patients

    This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment. Monoclonal antibodies, such as isatuximab, may interfere with the ability of cancer cells to grow and spread.

    Orange, California and other locations

  • Screening for AL Amyloidosis in Smoldering Multiple Myeloma

    Sorry, not yet accepting patients

    In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal of this study is to screen for the diagnosis of light-chain amyloidosis (AL) before the onset of symptomatic disease and to develop a training set for a likelihood algorithm.

    Orange, California and other locations

Our lead scientists for AL Amyloidosis research studies include .

Last updated: